UNIVERSITY OF UTAH RESEARCHERS DEVELOP FASTER, MORE ACCURATE TEST FOR LIVER CANCER THAT CAN BE ADMINISTERED ANYWHERE
It’s estimated that about 788,000 people worldwide died of liver cancer in 2015, the second-leading cause of cancer deaths, according to the latest statistics from the World Health Organization. One of the major challenges in combatting this disease is detecting it early because symptoms often don’t appear until later stages.
But a team of researchers led by University of Utah chemical engineering and chemistry professor Marc Porter and U surgeon and professor Courtney Scaife has developed a rapid portable screening test for liver cancer (hepatocellular carcinoma) that doesn’t involve sending a specimen to a blood lab and cuts the wait time for results from two weeks to two minutes. This new and inexpensive test — the team is working to lower the cost to about $3 per test — can be administered wherever the patient is, which will be particularly valuable in developing nations with little access to hospitals.
The test uses a small domino-sized plastic cartridge containing a paper membrane that selectively traps biomarkers (proteins specific to a certain disease) from biological fluids. A small droplet of blood, saliva, or urine, or even a teardrop, from the patient is dropped onto the membrane. This is followed by the droplet of gold nanoparticles, which tags the biomarkers trapped in the membrane. If the biomarkers are present, a red spot appears, signaling the patient has the disease and should seek more testing and possible treatment.
“The concept is similar to a home pregnancy test, but instead of flowing laterally, it flows through the membrane,” says Granger, the lead author on the paper.
A handheld spectrometer manufactured by project collaborator B&W Tek, a Delaware-based manufacturer of mobile spectrometers, can analyze the membranes and measure how much of the biomarkers is present, which in the future could determine the severity of the disease or how a patient is responding to treatment.
The idea for the test is a spinoff of a similar test Porter developed eight years ago that astronauts on the International Space Station used to test the cleanliness of their drinking water. “This is a smarter offshoot of that,” says Porter, who also is the director of the Nano Institute of Utah.
Now that the team has proven the concept with liver cancer and built a prototype test kit, researchers plan to evaluate the technology in Mongolia in spring of 2019. The East Asian country has the highest rate of liver cancer in the world.
The project was funded by grants from the National Institutes of Health, the National Cancer Institute through the Affordable Cancer Technologies Program and the Huntsman Cancer Institute. The team also received funding from Utah-based nutritional supplement company USANA which is interested in using a form of the test for customers with certain vitamin deficiencies.
“USANA has a keen interest in the ability to measure certain vitamins and biomarkers in various bodily fluids that can be related to a person’s health status,” said Mark Brown, Executive Director of Laboratory Sciences at USANA. “This would allow our customers to see for themselves the benefit of taking USANA’s high quality products. Rather than taking a blood sample and sending it off to lab for analysis, this technology could make it possible for people to do their own analysis in the comfort of their own home. Small sample size and simplicity of use are crucial components of making this a reality, and this research is a step closer to that end.”
Learn more: PUTTING IT TO THE TEST
The Latest on: Liver cancer
- Damon Runyon Cancer Research Foundation awards $4M to innovative early career scientistson January 22, 2020 at 10:17 am
Kimberley J. Evason, MD, PhD, and Gregory S. Ducker, PhD University of Utah One of the unique features of liver cancer is the way in which it obtains and uses different forms of energy, especially ...
- FDA grants orphan drug designation to durvalumab-tremelimumab combination for liver canceron January 21, 2020 at 10:52 am
“Many patients with liver cancer are diagnosed and treated only after the disease is advanced, and there is an urgent need for new effective and tolerable treatments,” José Baselga, MD, PhD, executive ...
- What are the main causes of liver cancer?on January 20, 2020 at 9:59 am
Liver cancer is a dangerous, highly fatal disease, so it is an obsession for many people. Liver cancer is alarming when 90% of liver cancer patients go to a doctor who has had previous viral hepatitis ...
- AstraZeneca liver cancer treatments win orphan FDA statuson January 20, 2020 at 8:03 am
Two AstraZeneca (NYSE:AZN) cancer drugs received have orphan status for treatment of liver cancer by the FDA, a designation that may eventually speed progress to approval. The special status was ...
- AstraZeneca Treatments Win Orphan FDA Status in Liver Canceron January 20, 2020 at 12:09 am
Two AstraZeneca Plc cancer drugs received orphan status for treatment of liver cancer, a designation that may eventually speed progress to approval.
- AstraZeneca: FDA gives orphan drug status to two liver cancer drugson January 19, 2020 at 10:55 pm
said Monday that two of its medicines were granted orphan drug status by the U.S. Food and Drug Administration for the treatment of a common type of liver cancer. The designation is awarded to drugs ...
- Kylee Dixon, teen with liver cancer who fled with mom, gets surgeryon January 16, 2020 at 8:49 pm
An Oregon teenager who was taken out of state by her mother to avoid surgery for a rare type of liver cancer has had the operation while in the custody of state welfare officials, several TV outlets ...
- Mount Sinai Research Finds that Heterogeneity of Liver Cancer Cells Help Explain Tumor Progression in Patientson January 16, 2020 at 5:08 pm
Many liver cancer tumors contain a highly diverse set of cells, a phenomenon known as intra-tumor heterogeneity that can significantly affect the rate at which the cancer grows, Mount Sinai ...
- Column: Nora Leonard died from liver cancer at 17. Andersonville park will honor the daughter of Second City execs.on January 16, 2020 at 9:43 am
A place that can live and breathe and grow, even as their daughter no longer gets to. Nora died in August from liver cancer. She was 17. Chicago Waldorf School, where Nora spent all of her school days ...
- Immune system contribution to tumor heterogeneity may influence liver cancer growthon January 15, 2020 at 2:12 pm
Researchers at Mount Sinai School of Medicine say the immune system might contribute to the tumor heterogeneity seen in liver cancer that can affect the rate of cancer growth. Liver tumors are often ...
via Google News and Bing News